The first half financial results of H. Lundbeck A/S showed a company in transition. While new products for schizophrenia and depression delivered double-digit sales increases, revenue for the company as a whole was down by 9% at DKK 8.5 billion (€1.13 billion) due to genetic competition for Onfi, a treatment for Lennox-Gastaut syndrome, a childhood epilepsy.
Earnings before interest and taxes (EBIT) were DKK 2.3 billion, down by 23%, giving an operating margin of 27.2%, down from 32.4% the previous year.